Culture

Study reveals how egg cells get so big

image: Clustered fruit fly nurse cells squeeze their contents into a large egg cell.

Image: 
Jasmin Imran Alsous

Egg cells are by far the largest cells produced by most organisms. In humans, they are several times larger than a typical body cell and about 10,000 times larger than sperm cells.

There's a reason why egg cells, or oocytes, are so big: They need to accumulate enough nutrients to support a growing embryo after fertilization, plus mitochondria to power all of that growth. However, biologists don't yet understand the full picture of how egg cells become so large.

A new study in fruit flies, by a team of MIT biologists and mathematicians, reveals that the process through which the oocyte grows significantly and rapidly before fertilization relies on physical phenomena analogous to the exchange of gases between balloons of different sizes. Specifically, the researchers showed that "nurse cells" surrounding the much larger oocyte dump their contents into the larger cell, just as air flows from a smaller balloon into a larger one when they are connected by small tubes in an experimental setup.

"The study shows how physics and biology come together, and how nature can use physical processes to create this robust mechanism," says Jörn Dunkel, an MIT associate professor of physical applied mathematics. "If you want to develop as an embryo, one of the goals is to make things very reproducible, and physics provides a very robust way of achieving certain transport processes."

Dunkel and Adam Martin, an MIT associate professor of biology, are the senior authors of the paper, which appears this week in the Proceedings of the National Academy of Sciences. The study's lead authors are postdoc Jasmin Imran Alsous and graduate student Nicolas Romeo. Jonathan Jackson, a Harvard University graduate student, and Frank Mason, a research assistant professor at Vanderbilt University School of Medicine, are also authors of the paper.

A physical process

In female fruit flies, eggs develop within cell clusters known as cysts. An immature oocyte undergoes four cycles of cell division to produce one egg cell and 15 nurse cells. However, the cell separation is incomplete, and each cell remains connected to the others by narrow channels that act as valves that allow material to pass between cells.

Members of Martin's lab began studying this process because of their longstanding interest in myosin, a class of proteins that can act as motors and help muscle cells contract. Imran Alsous performed high-resolution, live imaging of egg formation in fruit flies and found that myosin does indeed play a role, but only in the second phase of the transport process. During the earliest phase, the researchers were puzzled to see that the cells did not appear to be increasing their contractility at all, suggesting that a mechanism other than "squeezing" was initiating the transport.

"The two phases are strikingly obvious," Martin says. "After we saw this, we were mystified, because there's really not a change in myosin associated with the onset of this process, which is what we were expecting to see."

Martin and his lab then joined forces with Dunkel, who studies the physics of soft surfaces and flowing matter. Dunkel and Romeo wondered if the cells might be behaving the same way that balloons of different sizes behave when they are connected. While one might expect that the larger balloon would leak air to the smaller until they are the same size, what actually happens is that air flows from the smaller to the larger.

This happens because the smaller balloon, which has greater curvature, experiences more surface tension, and therefore higher pressure, than the larger balloon. Air is therefore forced out of the smaller balloon and into the larger one. "It's counterintuitive, but it's a very robust process," Dunkel says.

Adapting mathematical equations that had already been derived to explain this "two-balloon effect," the researchers came up with a model that describes how cell contents are transferred from the 15 small nurse cells to the large oocyte, based on their sizes and their connections to each other. The nurse cells in the layer closest to the oocyte transfer their contents first, followed by the cells in more distant layers.

"After I spent some time building a more complicated model to explain the 16-cell problem, we realized that the simulation of the simpler 16-balloon system looked very much like the 16-cell network. It is surprising to see that such counterintuitive but mathematically simple ideas describe the process so well," Romeo says.

The first phase of nurse cell dumping appears to coincide with when the channels connecting the cells become large enough for cytoplasm to move through them. Once the nurse cells shrink to about 25 percent of their original size, leaving them only slightly larger than their nuclei, the second phase of the process is triggered and myosin contractions force the remaining contents of the nurse cells into the egg cell.

"In the first part of the process, there's very little squeezing going on, and the cells just shrink uniformly. Then this second process kicks in toward the end where you start to get more active squeezing, or peristalsis-like deformations of the cell, that complete the dumping process," Martin says.

Cell cooperation

The findings demonstrate how cells can coordinate their behavior, using both biological and physical mechanisms, to bring about tissue-level behavior, Imran Alsous says.

"Here, you have several nurse cells whose job it is to nurse the future egg cell, and to do so, these cells appear to transport their contents in a coordinated and directional manner to the oocyte," she says.

Oocyte and early embryonic development in fruit flies and other invertebrates bears some similarities to those of mammals, but it's unknown if the same mechanism of egg cell growth might be seen in humans or other mammals, the researchers say.

"There's evidence in mice that the oocyte develops as a cyst with other interconnected cells, and that there is some transport between them, but we don't know if the mechanisms that we're seeing here operate in mammals," Martin says.

The researchers are now studying what triggers the second, myosin-powered phase of the dumping process to start. They are also investigating how changes to the original sizes of the nurse cells might affect egg formation.

Credit: 
Massachusetts Institute of Technology

Protein controlling magnesium identified as therapeutic target for non-alcoholic fatty liver disease

image: The study identified the CNNM4 protein as a key regulator of magnesium (Mg) in the liver and potential therapeutic target for non-alcoholic fatty liver disease (NASH).

Image: 
CIC bioGUNE

An international team of researchers has identified the CNNM4 protein as a key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease, according to a study published in the Journal of Hepatology.

Non-alcoholic steatohepatitis, a form of fatty liver disease characterized by inflammation and liver fibrosis, is associated with obesity and has a worldwide prevalence of 1.7 billion people.

Unhealthy nutritional habits and dietary imbalances are recognized as causes of many diseases. Magnesium is widely available in both plant and animal foods; most vegetables, legumes, peas, beans, and nuts are rich in magnesium, as are some seafood and spices. In recent years, there has been growing concern about inadequate magnesium intake in the general population. According to the National Health and Nutrition Examination Survey (NHANES), 79% of U.S. adults do not meet the recommended intake of magnesium.

In the Journal of Hepatology study--led by Malu Martínez Chantar, principal investigator of the Liver Disease Laboratory at Spain's CIC bioGUNE and CIBER de Enfermedades Hepáticas y Digestivas (CIBEREHD), and Jorge Simon, first author of the publication--the researchers found a higher expression of the CNNM4 protein in both patients with non-alcoholic steatohepatitis and mouse models of the disease. CNNM4 facilitates transport of magnesium out of the liver and is responsible for the imbalance in the levels of magnesium that ends in the development of liver disease.

"These patients have an altered magnesium export machinery that increases the vulnerability of their liver to suffer inflammatory processes, development of fibrosis and fat deposition," explains Martínez Chantar. "This study also presents a novel therapeutic approach based on GalNac-siRNA technology that specifically targets the liver by modulating CNNM4 levels. The CNNM4 molecule developed from Silence Therapeutics' proprietary mRNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform effectively protects from liver pathology in preclinical models of steatohepatitis."

This molecule opens an unexplored therapeutic window in non-alcoholic fatty liver disease.

"The study underscores the importance of magnesium balance for supporting liver health. With insight into how this essential metal affects lipid metabolism at the cellular level, possible therapeutic targets for this and other liver pathologies start emerging," says Daniela Buccella, associate professor of chemistry at New York University and a study co-author.

Credit: 
New York University

High-resolution ocean model provides insight into sea turtles' lost years

image: An animation depicting how baby sea turtles likely disperse from a nesting site in Japan into the open ocean. The "turtles" are green particles in this simulation, which was run using a high-resolution version of the NCAR-based Community Earth System Model.

Image: 
Cheryl Harrison

An exquisitely detailed global ocean model simulation from the National Center for Atmospheric Research (NCAR) has given scientists rare insight into where baby sea turtles may go in their "lost years" after they scramble off the sandy beaches where they are born and swim into the open ocean.

This look at a critically important period in the life cycle of endangered loggerhead turtles could help inform more comprehensive conservation efforts that encompass regions of the open ocean where young turtles grow, and not just the nesting beaches. It also pinpoints regions of the ocean that are important to study to better understand how to protect sea turtles.

"To understand where sea turtle hatchlings are being swept to when they enter the open ocean -- and how favorable that habitat is to turtle survival -- we need to simulate smaller scale ocean features, the jets and eddies that transport these younglings," said Cheryl Harrison, a researcher at the University of Texas Rio Grande Valley, who led the study. "The models typically used to simulate global ocean movement are too coarse for us to resolve these important features. The really exciting thing about this study is we were able to use a high-resolution, eddy-resolving model to track where turtles are traveling."

The ocean simulation used for the new study, published in the journal Royal Society Interface, was run using the NCAR-based Community Earth System Model at a resolution that is an order of magnitude higher than standard global modeling runs. The model also contains complex biogeochemistry, which allowed the researchers to estimate food availability along the turtles' path.

The research was funded by the National Science Foundation, which is NCAR's sponsor, NASA, and the U.S. Department of Energy. Harrison began work on the study as a postdoctoral researcher at NCAR, working with oceanographer Matthew Long, who co-authored the study. Harrison is now an assistant professor at the University of Texas Rio Grande Valley.

Finding the lost years

Loggerhead turtles nest on specific beaches scattered around the globe, often where strong currents come close to land. After hatching, the baby turtles head for the ocean, where they spend the next several years as they mature. Once they reach sexual maturity decades later, the turtles eventually return to the beach where they were born to mate and lay their own eggs before the cycle begins again.

For the new study, Harrison and her colleagues studied how hatchlings are likely to disperse during the first year of their lives from nesting sites on the coasts of Japan, Florida, Cape Verde, Oman, west Australia, east Australia, Brazil, and South Africa. Because the baby sea turtles must stay near the surface of the ocean to breathe -- and because they are not yet able to swim for significant periods -- the researchers were able to emulate their possible journeys using a method known as particle tracking, which follows how particles "released" into the model move with simulated water trajectories over time.

The results show that at many of the nesting sites, strong nearby currents -- including the Kuroshio, Gulf Stream, Brazil, and Agulhas currents -- sweep the turtles poleward to a region of ocean where two circular ocean currents (known as gyres) come together. This boundary between the subpolar and subtropical gyres is warm enough for the hatchlings to survive and also rich with zooplankton and other food that turtles depend on to survive.

The study results help demarcate the regions where turtles from each beach are going in their "lost years" when ecologists cannot easily keep tabs on them. For example, turtles born in southeastern Florida travel with the Gulf Stream all the way to the Azores, a productive and warm ocean habitat perfect for nurturing them.

At other nesting sites, such as the one on the coast of Oman, the hatchlings do not hitch a ride on a strong current to far-off ocean habitats. Instead, they use a local current that disperses them relatively nearby because the area waters are already suitable for the young turtles. This understanding of where the turtles go allows scientists to better understand what threats the turtles may be facing.

"Sea turtle hatchlings are very difficult to track and observe as they have high mortality rates and grow out of tags quickly," Harrison said. "Modelling studies help us close this observational gap and predict where they are going in the 'lost years.' Identifying ocean habitat helps us understand what factors are important for their survival in this life stage."

Credit: 
National Center for Atmospheric Research/University Corporation for Atmospheric Research

Digital app can help chronic pain sufferers manage their pain

Digital solutions including remote monitoring can help chronic pain sufferers manage their pain and reduce the probability of misuse of prescription opioids.

For chronic pain sufferers an app may be just the tool they need to manage their pain. In a UHN-led study that used the app "Manage My Pain" enrolled patients saw clinically significant reductions in key areas that drive increased medical needs, potential abuse of prescription opioids and of course, pain.

Toronto (March 4, 2021) - For the first time, an app has been shown to reduce key symptoms of chronic pain. A UHN-led study evaluated the impact of Manage My Pain (MMP), a digital health solution developed by ManagingLife, on patients seen at the Iroquois Falls Family Health Team, and the Toronto Western and Toronto General Hospitals.

Published today in JMIR mHealth, a leading peer-reviewed journal focused on health and biomedical applications, the study showed patients who used the MMP app saw a clinically significant reduction in anxiety and pain catastrophizing, two key areas that drive increased medical needs and potential abuse of prescription opioid.

"Manage My Pain has helped our patients tell their story," says Dr. Hance Clarke, Director Pain Services, Medical Director of The Pain Research Unit, Toronto General Hospital, UHN. "As a result, this has empowered them to engage in discussions that enabled us to come up with patient-centered treatment plans to help manage their pain."

246 participants with chronic pain were enrolled in the study and more than 70 per cent of the group agreed to use the app along with their medication, psychological therapy, and physiotherapy, the other 30 per cent were the control group. The app allowed them to track their pain, create reports that facilitated better communication with their care providers, and through a virtual portal, give clinicians the ability to remotely monitor their patients and use advanced analytics to spot any negative trends weeks and months in advance.

"Prior to Manage My Pain, our clinic was dependent on paper-based questionnaires to understand a patient's pain experience and response to treatment," says Dr. Anuj Bhatia, Site Director, Anesthesia - Interventional Pain Service, Toronto Western Hospital, UHN. "The app allows us to capture even more information than we had previously, while doing so digitally and remotely. The app also allowed us to study trends in intensity of pain and its impact on the patients' lives."

Patients were prompted daily to record their reflections in the app. In less than a minute, they could input the activities they were able to accomplish and rate the pain they felt. In return, they received charts and graphs that highlighted patterns and trends that could increase their self-awareness, and provide insight into triggers and interventions.

For the rural patients involved in this study, the benefits of MMP were remarkably clear from the beginning. Lacking a speciality pain centre, patients in Iroquois Falls must rely on their primary caregivers and the app made the communication between the patient-clinician easier and more productive.

"Chronic pain isn't like a broken arm," says Dr. Auri Bruno-Petrina, rural Physician, Iroquois Falls. "It can be invisible to the naked eye, so people who suffer from it can find it very frustrating to explain how they are feeling and how much it is impacting their lives. This app strengthened my ability to help my patients because we had more nuanced data and we could really dig into the details."

For both rural and urban patients suffering from chronic pain, the use of MMP encouraged tracking and reflecting, both of which are important components of most self-management programs. The ease of adoption also presents a positive opportunity for engaging with patients during significant challenges like the one presented by the COVID-19 pandemic.

"The COVID-19 pandemic has shown us how essential it is for patients to have a role in managing healthcare conditions," says Dr. Clarke. "Digital tools like Manage My Pain are a great way to empower self-management in patients, which is one of the hallmarks of successful clinical care."

Credit: 
University Health Network

'PopDel' detects deletions in our genomes

The human genome contains roughly three million letters. On average, the genome sequences of any two people differ from each other by about one in every 1,000 letters. Yet different variants occur, from substituted letters to entire missing sections of DNA. Scientists from the Berlin Institute of Health (BIH) and the Regensburg Center for Interventional Immunology (RCI) have teamed up with Icelandic researchers to develop software that reliably and quickly identifies large deletions in ten-thousands of genomes simultaneously. The researchers have now published their findings in the journal Nature Communications.

The human genome contains roughly three million letters and is distributed over 46 chromosomes. Yet the genetic variation from person to person is very small: the genome sequences of any two people differ from each other by about one in every 1,000 letters. Sometimes single letters are exchanged in the genome, while other times whole sections are moved around. "Many of these differences go unnoticed, because they do not affect the structure of the proteins encoded in the genome and do not cause any diseases," says Birte Kehr, a junior group leader at the Berlin Institute of Health (BIH) who was recently appointed professor at the Regensburg Center for Interventional Immunology (RCI). The bioinformatician is working on so-called structural variants, in which larger segments of the genome are deleted, duplicated or even swapped between chromosomes.

Large structural changes have a big impact

"Large structural changes are much rarer than changes in single letters," Kehr explains, "but they often have a bigger impact and are also harder to detect." To learn more about these bigger changes, it is helpful to use large databases to search for them. That's where the collaboration with the Icelandic company deCODE Genetics came in, whose database contains some 50,000 human genome sequences and where Kehr formerly worked as a postdoc. "We always planned to search for deletions in the data, but we didn't have a program capable of reliably and quickly processing such huge amounts of data." When Kehr joined the BIH in Berlin, she gave this task to her first Ph.D. student, Sebastian Niehus.

Data is valuable only if it is used

The programs previously available for identifying structural variants such as deletions could only process data from a few individuals at a time. For large data sets, such as those in the deCODE genome database, the results then had to be combined, which was a cumbersome and error-prone process. "We first wanted to develop a statistical model that would enable us to evaluate information from all genomes simultaneously," Niehus reports. "To do this, the program had to be designed so that a computer could quickly sift through huge quantities of data. We also had to compress the files to 1 to 2 percent of their original size to be able to work with them at all."

Faster and more accurate than other software

Once a prototype was developed, the PopDel program had to prove itself against other programs in various scenarios. These included simulated sequence data from up to 1,000 "individuals"; sequence data from 49 parent-child trios, which allowed a thorough analysis of whether inheritance patterns were reconstructed correctly; sequence data from 150 individuals of different ethnicities, which made it possible to evaluate population structures; and finally the approximately 50,000 genomes from the Icelandic cooperation partner deCODE Genetics.

"We were able to show that PopDel produced good results in a quick, reliable and resource-efficient way, both with data from a single person and with data from the largest cohorts," Niehus reports with pride. Kehr adds: "PopDel only needed two days to analyze the genomes of 150 individuals where other programs had taken four weeks. And PopDel's results were better."

Rare gene variant discovered

The highlight for the researchers was the discovery of a rare, previously unknown gene variant in only one family out of the 50,000 Icelanders analyzed. "The gene for the LDL receptor showed a larger deletion, or gap, in these family members. This was coupled with very low levels of cholesterol in these individuals," explains Kehr. Her collaborators at deCODE Genetics have since been able to show that the change in the LDL receptor gene is indeed responsible for the low cholesterol levels in affected individuals. "One affected individual died at the age of 85, while six other affected individuals aged 35 to 65 are all very healthy with their low cholesterol levels," says Kehr. "The results are therefore also very interesting from a medical point of view, because we seem to have discovered a genetic variant that contributes to healthy lipid metabolism."

In the next step, the researchers want to develop the program further. They are continuing to work on it themselves, but have also deposited PopDel's source code on an open server so that anyone can view, use and improve it. "PopDel can so far only detect deleted DNA segments, but there are also genetic variants where segments have been duplicated, inverted or translocated. We would now like to find all of them with PopDel as well," says Niehus, looking to the future. And Kehr hopes that, in the long run, the findings will lead to the development of new therapies and treatment approaches -in keeping with BIH's motto of "Turning Research into Health."

Credit: 
BIH at Charité

Performance of methane conversion solid catalyst is predicted by theoretical calculation

image: Mole fraction along the reaction time (s) calculated by the reactor simulation. The inlet gas consisted of CH4, O2, and He (as inert gas). The total pressure was set to P = 1 bar, and the partial pressure ratio of CH4, O2, and He was set to 2:1:4. The volumetric flow rate was set to 1 mL/s, and the reaction temperature was 700 °C. The catalyst weight was 1 g.

Image: 
Atsushi Ishikawa

Japanese researchers have developed a simulation method to theoretically estimate the performance of heterogeneous catalyst by combining first-principles calculation (1) and kinetic calculation techniques. Up to now, simulation studies mainly focused on a single or limited number of reaction pathways, and it was difficult to estimate the efficiency of a catalytic reaction without experimental information.

Atsushi Ishikawa, Senior Researcher, Center for Green Research on Energy and Environmental Materials, National Institute for Materials Science (NIMS), performed computation of reaction kinetic information from first-principles calculations based on quantum mechanics, and developed methods and programs to carry out kinetic simulations without using experimental kinetic results. Then he applied the findings to the oxidative coupling of methane (OCM) reaction, which is an important process in the use of natural gas. He could successfully predict the yield of the products, such as ethane, without experimental information on the reaction kinetics. He also predicted changes in yield depending on the temperature and partial pressure, and the results reproduced faithfully the existing experimental results.

This research shows that the computer simulation enables the forecasting the conversion of reactant and the selectivity of products, even if experimental data are unavailable. The search for catalytic materials led by theory and calculation is expected to speed up. Furthermore, this method is highly versatile and can be applied not only to methane conversion catalysts but also to other catalyst systems such as for automobile exhaust gas purification, carbon dioxide reduction and hydrogen generation, and is expected to contribute to the realization of a carbon-free society.

Credit: 
Japan Science and Technology Agency

Quick to smile - study shows speed of expression offers vital visual cues

The speed at which we produce facial expressions plays an important role in our ability to recognise emotions in others, according to new research at the University of Birmingham.

A team in the University's School of Psychology carried out research which showed that people tend to produce happy and angry expressions more rapidly, while sad expressions are produced more slowly.

The team found that our ability to form judgements about people's facial expressions has close links with the speeds at which those expressions are produced and is also closely related to the ways in which we would produce those expressions ourselves. The study is published in Emotion.

"Being able to recognise and interpret facial expressions is a vital part of social interaction," explained lead author Dr Sophie Sowden. "While we understand the spatial characteristics of an expression - the way the mouth moves in a smile, for example - the speeds at which expressions are produced are often overlooked. The ability to pick up on and rapidly interpret these cues could also help people to judge facial expressions even when mask-wearing might limit other visual cues."

Dr Sowden added: "Better understanding how people interpret this important visual cue, could give us new insights into the diagnosis of conditions such as Autism Spectrum Disorder or Parkinson's Disease. This is because patients with these conditions often recognise facial expressions differently, or exhibit expressions differently."

In the study, the team asked people to create facial expressions directed at a camera, and used an opensource software programme called OpenFace to track their facial movement. They measured the speed of movement in regions of the face known to be important in producing expression, including around the eyebrows, the nose and the mouth, as well as across the face as a whole.

In the first part of the experiment, the researchers investigated the average speed at which participants produced different expressions. They were asked to produce 'posed expressions', as well as expressions during speech, and spontaneous expressions were recorded in response to emotion-inducing videos. Interestingly, they showed differences in speed across emotions depends on the region of the face and the 'type' of expression being considered.

In a second phase of the study, the team investigated what would happen if they captured schematic versions of facial expressions being produced, and manipulated the speeds involved. In this experiment, the researchers found that as the act of expression was speeded up, people would get better at recognising it as happy or angry, whereas if it was slowed down, people would more accurately identify it as sad.

As well as being important for early diagnosis of autism and Parkinson's disease, the researchers believe the work could also be useful in a range of artificial intelligence applications such as facial recognition software.

Credit: 
University of Birmingham

Does a vegan diet lead to poorer bone health?

The vegan diet is on trend. How this type of diet affects health is the subject of scientific studies. In a new study from the German Federal Institute for Risk Assessment (BfR), the bone health of 36 vegans as well as 36 people following a mixed-food diet was determined with an ultrasound measurement of the heel bone. The result: on average, people following a vegan diet had lower ultrasound values compared to the other group. This indicates poorer bone health.

In the study, the scientists also determined biomarkers in blood and urine. This aims to identify nutrients that might be related to diet and bone health. Out of 28 parameters of nutritional status and bone metabolism, it was possible to identify twelve biomarkers most strongly associated with bone health - for example, the amino acid lysine and vitamins A and B6. The results show that in most cases, the combination of these biomarkers was present in lower concentrations in vegans. This could be a possible explanation for the poorer bone health. "A vegan diet is often considered health-conscious. However, our scientific findings indicate that a vegan diet does affect bone health," says BfR President Professor Dr. Dr. Andreas Hensel.

Link to publication:
https://www.mdpi.com/2072-6643/13/2/685/htm

Nutrition plays an important role in bone health. This was more closely investigated in the BfR's cross-sectional "Risks and benefits of a vegan diet" study. 72 men and women participated in the study. The bone health of all participants was assessed at the heel bone using ultrasound measurements. Information on age, smoking status, education, body mass index, physical activity and alcohol consumption was also collected. By using a statistical model, the BfR was able to identify a pattern of twelve biomarkers that play an important role in bone health from 28 nutrition- and bone-relevant parameters from blood or urine. It was shown that in combination vitamins A and B6, the amino acids lysine and leucine, omega-3 fatty acids, selenoprotein P, iodine, thyroid-stimulating hormone, calcium, magnesium and α-Klotho protein were positively associated with bone health. Conversely, lower concentrations of the hormone FGF23 were observed at higher ultrasound levels in this pattern.

Taking into account other scientific studies, the results indicate that vegans intake fewer nutrients that are relevant for the skeleton and are mainly found in food of animal origin. Further studies are needed for clarification.

Credit: 
BfR Federal Institute for Risk Assessment

Clinical relevance of patient-reported outcomes: new threshold proven feasible in practice

In order to show the clinical relevance of a difference between two treatment alternatives, in recent years, the manufacturer dossiers submitted in early benefit assessments of new drugs have increasingly contained responder analyses for patient-relevant outcomes. In such analyses, it is investigated whether the proportion of patients experiencing a noticeable change in the respective outcome differs between the two treatment groups in a study. This involves information on health-related quality of life or on individual symptoms such as pain or itching, which patients recorded with the help of scales in questionnaires.

But what difference makes a change relevant for the individual? That is, at what threshold can a response to an intervention be derived for the patient, so that, for example, the difference in the response rates of two groups can be used as an effect measure for early benefit assessments?

When is a difference relevant?

To answer this question, the methodological discussion has long revolved around so-called minimally important differences (MID). This approach is based on the idea that thresholds can be identified for the respective questionnaires that represent the smallest relevant change for patients. However, the methodological problems of this approach have recently become apparent. For instance, it has been shown that an MID is not a fixed value for a questionnaire, but is variable. It depends, for example, on the type and severity of a disease, the direction of a change (improvement or deterioration) or the methods used to determine it.

Furthermore, it has become clear that many scientific studies on the determination of an MID no longer meet today's methodological standards or that the methodology used is inadequately described in the scientific publications. In this situation, IQWiG has developed a new approach that makes it possible to easily determine thresholds delimiting a relevant range with sufficient certainty. The aim of this specification was also to create clarity for manufacturers and to make arbitrary responder analyses based on incomprehensible responder definitions unattractive.

Concerns were unfounded

From an evaluation of new scientific reviews on the topic, last year IQWiG therefore identified a value of 15% of the range of the respective scales as a plausible threshold for a relatively small, but sufficiently certain noticeable change. In its General Methods 6.0 published in November 2020, the Institute then specifically stated that in future assessments, it would use responder analyses from a threshold of at least 15% of the scale range of the measurement instrument used.

The strict stipulation of the 15% threshold for the acceptance of responder analyses in IQWiG assessments triggered discussions in the run-up to the General Methods 6.0. Among other things, some manufacturers feared that this approach would not be applicable to all scales and that proving the added benefit of a new drug would thus be made more difficult. On the occasion of the addenda published today on early benefit assessments of the drugs secukinumab (for psoriatic arthritis), ivacaftor (for cystic fibrosis) and alpelisib (for breast cancer), Katrin Nink from IQWiG's Drug Assessment Department emphasizes: "The concerns were unfounded. We see that the new threshold is suitable for use in practice." In the assessments in question, the manufacturers subsequently submitted the requested data so that the Institute could use the responder analyses for its assessments.

This applies to several questionnaires on both the burden of disease symptoms and on health-related quality of life in quite different indications such as cystic fibrosis in children, psoriatic arthritis or breast cancer. Nink further explains: "Based on analyses with the new response thresholds, we were able to show the advantages and disadvantages of treatments, such as the advantage of ivacaftor for the quality of life of children with cystic fibrosis. So the new generic criterion works."

Credit: 
Institute for Quality and Efficiency in Health Care

Do known drugs help against SARS-coronavirus-2?

image: (A) SARS-CoV-2 attaches to human cells through binding of its spike protein to the cellular protein ACE2. Next, SARS-CoV-2 exploits human enzymes like the protease TMPRSS2 for the activation of its spike protein, which subsequently fuses the viral membrane with a target cell membrane and thus allow the delivery of the viral genetic information into the cell.
(B) Apart from TMPRSS2, SARS-CoV-2 can utilize other proteases for spike protein activation. Among them are TMPRSS11D and TMPRSS13, which are mainly expressed in the upper respiratory tract. The anti-pancreatitis drugs Camostat (as well as its metabolite GBPA) and Nafamostat not only block TMPRSS2 but also TMPRSS11D and TMPRSS13. As a consequence, switching from TMPRSS2 to TMPRSS11D or TMPRSS13 as activators does not allow SARS-CoV-2 to escape Camostat's/Nafamostat's antiviral activity.

Image: 
Markus Hoffmann

There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing of already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development. The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells. However, it was previously unknown whether SARS-CoV-2 can use TMPRSS2-related proteases for cell entry and whether these proteases can be blocked by Camostat. Moreover, it was unclear whether metabolization of Camostat interferes with antiviral activity. An international team of researchers around Markus Hoffmann and Stefan Pöhlmann from the German Primate Center (DPZ) - Leibniz Institute for Primate Research has now shown that SARS-CoV-2 can use several TMPRSS2-related proteases for its activation. These proteases are expressed in the upper respiratory tract and are blocked by Camostat. In addition, the researchers found that Camostat and its major metabolite GBPA inhibit SARS-CoV-2 infection of primary human lung tissue. These findings support the further development of Camostat and related compounds for COVID-19 therapy (EBioMedicine).

SARS-CoV-2 depends on activation by the cellular protease TMPRSS2 for infection of lung cells. The researchers of the Infection Biology Unit of DPZ previously documented that the drugs camostat and nafamostat, which are used in Japan to treat inflammation of the pancreas, block SARS-CoV-2 infection by inhibiting TMPRSS2. However, it was unknown whether Camostat metabolites also block SARS-CoV-2 and whether the virus may use TMPRSS2-related proteases for infection that may be Camostat-insensitive.

An international team of researches around Markus Hoffmann and Stefan Pöhlmann from the Infection Biology Unit of the DPZ has now shown that SARS-CoV-2 can use several TMPRSS2-related proteases for infection, among them TMPRSS11D and TMPRSS13. These proteases may support viral spread in the upper respiratory tract and are blocked by Camostat. This finding indicates that switching to activators other than TMPRSS2 might not allow the virus to replicate in the presence of Camostat.

The researchers could show that not only Camostat but also a major Camostat-metabolite, GBPA, block TMPRSS2 and SARS-CoV-2 infection. "In the human body Camostat is rapidly converted to GBPA. Therefore, it was crucial to demonstrate that not only Camostat but also GBPA exert antiviral activity", says Stefan Pöhlmann, the head of the Infection Biology Unit of DPZ. Markus Hoffmann, the first author of the study adds: "Our results suggest that Camostat/GBPA may unfold antiviral activity in patients. However, for effective treatment of COVID-19, a higher Camostat dose might be required as compared to pancreatitis treatment."

Inhibition of SARS-CoV-2 by Camostat was initially shown using the lung cell line Calu-3. The participation of Armin Braun, Fraunhofer ITEM, Hannover, and Danny Jonigk, Institute of Pathology at the MHH, in the consortium allowed analysis of Camostat antiviral activity in primary human lung tissue ex vivo. Camostat and GBPA blocked SARS-CoV-2 infection of lung tissue and Nafamostat had an increased antiviral activity. Therefore, the team of the Infection Biology Unit and the laboratory of Armin Braun are investigating how Nafamostat can be directly delivered into the human lung for increased antiviral activity. This project receives financial support from the Bundesministerium für Bildung und Forschung (BMBF) (project RENACO, Repurposing of Nafamostatmesylat for treatment of COVID-19).

"Our results on the antiviral activity of Camostat and GBPA are relevant beyond the treatment of COVID-19. TMPRSS2 also plays an important role in other respiratory infections. Thus, Camostat could also be successfully used to treat influenza," says Markus Hoffmann.

Credit: 
Deutsches Primatenzentrum (DPZ)/German Primate Center

March science snapshots

image: This scanning electron microscope image shows SARS-CoV-2 emerging from the surface of cells (blue/pink) cultured in the lab.

Image: 
National Institute of Allergy and Infectious Diseases-Rocky Mountain Laboratories, NIH

Solving a Genetic Mystery at the Heart of the COVID-19 Pandemic

As the COVID-19 pandemic enters its second year, scientists are still working to understand how the new strain of coronavirus evolved, and how it became so much more dangerous than other coronaviruses, which humans have been living alongside for millennia.

Virologists and epidemiologists worldwide have speculated for months that a protein called ORF8 likely holds the answer, and a recent study by Berkeley Lab scientists has helped confirm this hypothesis.

In a paper published in mBio, lead author Russell Neches and his colleagues show that ORF8 evolved from another coronavirus protein called ORF7a, and that both proteins have folds similar to that of a human antibody. This finding helps to explain how the virus avoids immune detection and is able to escalate into a severe infection in some hosts.

"By exploring the structural and functional characteristics of ORF8, and using supercomputers to look at the genomes of over 200,000 viruses, we discovered a striking and highly unusual evolutionary strategy," said co-author Nikos Kyrpides, a computational biologist at the DOE Joint Genome Institute (JGI). "Amazingly, it seems that within the SARS clade, the gene encoding ORF7a is used as a 'template' gene, remaining stable, with a duplicate copy of this gene evolving to a point almost beyond recognition." SARS-CoV-2 arose and exploded into a pandemic when a SARS strain's duplicate ORF7a gene happened to mutate leading to a new protein (which we now call ORF8) that gave it the ability to interfere with immune cells.

According to the team, a similar event occurred in the SARS-CoV strain that caused the SARS epidemic in the early 2000s. In that instance, a copy of the ORF7a gene split into two, resulting in ORF8a and ORF8b proteins.

Christos Ouzounis, senior author of the study and a JGI affiliate scientist, noted that the connection between ORF8 and ORF7a was initially quite difficult to make, due to how little was known about this set of genes and their encoded proteins compared with the existing knowledge about surface proteins (such as the infamous spike protein), and because ORF8 and ORF7a currently seem wildly different. ORF7a is highly stable, mutation resistant protein that interacts with very few mammalian host proteins, whereas ORF8 is encoded by the most mutation prone gene in the viral genome, and is now known to be involved in dozens of interactions in the human body.

"Our findings - and their confirmation by parallel sequence and structure studies - reveal ORF8 to be an evolutionary hotspot in the SARS lineage. The lack of knowledge about the role of these genes has diverted attention to the more well-understood genes, but we now know more about this gene and hopefully it will receive more attention from the community," said Kyrpides.

This work was supported by the ExaBiome Project, a Berkeley Lab-led collaboration which develops supercomputing tools for microbiome analysis. JGI is an Office of Science user facility.

Assessing the Costs of Major Power Outages

Little is known about the full impact of widespread, long duration power interruptions, especially the indirect costs and related economy-wide impacts of these events. As a result, the costs of such power interruptions are generally not or only incompletely considered in utility planning activities.

A new Berkeley Lab report titled "A Hybrid Approach to Estimating the Economic Value of Enhanced Power System Resilience" describes a new approach for estimating the economic costs of widespread, long duration power interruptions, such as the one that occurred recently in Texas. This hybrid method involves using survey responses from utility customers to calibrate a regional economic model that is able to estimate both the direct and indirect costs of these events.

"We believe that this paper is an important breakthrough for researchers interested in estimating the full economic impact of widespread, long duration power disruptions," said Berkeley Lab researcher Peter Larsen.

A second report, titled "Case Studies of the Economic Impacts of Power Interruptions and Damage to Electricity System Infrastructure from Extreme Events," analyzes in detail the economics of power interruptions caused by extreme weather. The researchers examined the effects of Hurricane Harvey in Texas, wildfires in California, and four other extreme events; they found that even years after the events, utility companies had a clear picture of the costs of physical repairs but had not tallied the human and societal costs of the outages. (Researchers from the University of Texas at Austin were co-authors of this report; read their news release about the report here.)

"Our research shows that utilities, regulators, and other stakeholders rarely, if ever, account for the direct and indirect costs of power disruptions in their decision-making," Larsen said.

Location, Location, Location: Regional Tau Deposits in Healthy Elders Predict Alzheimer Disease

Subtle memory deficits are common in normal aging as well as Alzheimer disease (AD), the leading cause of dementia in older adults. This makes AD difficult to diagnose in its early stages. As there is currently no effective treatment to slow or stop the progression of AD, it is important to identify early pathological brain changes, which can start decades before people show symptoms, and then trace the effects that lead to cognitive decline.

Xi Chen and her colleagues in Bill Jagust's research group at Berkeley Lab recently published a study in the Journal of Neuroscience that provides some clarification of the differences between normal aging and AD brains, and elucidates the transition from the former to the latter.

Using positron emission tomography (PET) imaging, they measured levels of tau and beta amyloid (Aß) - two critical biomarkers of AD - in cognitively normal older adults, and then followed them for several years for prospective cognition assessment. Their findings revealed new insight into tau, a protein that helps stabilize the internal skeleton of neurons in its normal form, but becomes unstable and can interfere with neuron functioning when aggregated. Aggregated tau deposits in the entorhinal cortex, a major part of the memory system, likely reflect normal, age-related memory impairment. However, tau deposits in anterior temporal regions of the brain - responsible for our knowledge of objects, people, words, and facts - were most predictive of AD-related impairment. The finding supports a model of early AD pathology proposed by the researchers whereby tau spreads from the entorhinal cortex to anterior temporal regions facilitated by amyloid.

The team suggests that the presence of tau aggregates in anterior temporal regions could be used as a marker of early disease progression.

New Optical Antennas Could Overcome Data Limits

Researchers at Berkeley Lab and UC Berkeley have found a new way to harness properties of lightwaves that can radically increase the amount of data they carry. They demonstrated the emission of discrete twisting laser beams from antennas made up of concentric rings roughly equal to the diameter of a human hair, small enough to be placed on computer chips.

The new work, reported in a paper published Feb. 25 in the journal Nature Physics, throws wide open the amount of information that can be multiplexed, or simultaneously transmitted, by a coherent light source. A common example of multiplexing is the transmission of multiple telephone calls over a single wire, but there had been fundamental limits to the number of coherent twisted lightwaves that could be directly multiplexed.

"It's the first time that lasers producing twisted light have been directly multiplexed," said senior author Boubacar Kanté, a faculty scientist in Berkeley Lab's Materials Sciences Division and the Chenming Hu Associate Professor in UC Berkeley's Department of Electrical Engineering and Computer Sciences. "We've been experiencing an explosion of data in our world, and the communication channels we have now will soon be insufficient for what we need. The technology we are reporting overcomes current data capacity limits through a characteristic of light called the orbital angular momentum. It is a game-changer with applications in biological imaging, quantum cryptography, high-capacity communications and sensors."

Read the full UC Berkeley release here.

Credit: 
DOE/Lawrence Berkeley National Laboratory

Cutting off stealthy interlopers: a framework for secure cyber-physical systems

image: The trio of authors from the Department of Information and Communication Engineering at DGIST; Professor Kyung-Jun Park (right), Professor Yongsoon Eun (left), and Sangjun Kim (middle; integrated Master's and PhD student)

Image: 
dgist

In 2015, hackers infiltrated the corporate network of Ukraine's power grid and injected malicious software, which caused a massive power outage. Such cyberattacks, along with the dangers to society that they represent, could become more common as the number of cyber-physical systems (CPS) increases.

A CPS is any system controlled by a network involving physical elements that tangibly interact with the material world. CPSs are incredibly common in industries, especially those integrating robotics or similar automated machinery to the production line. However, as CPSs make their way into societal infrastructures such as public transport and energy management, it becomes even more important to be able to efficiently fend off various types of cyberattacks.

In a recent study published in IEEE Transactions on Industrial Informatics, researchers from Daegu Gyeongbuk Institute of Science and Technology (DGIST), Korea, have developed a framework for CPSs that is resilient against a sophisticated kind of cyberattack: the pole-dynamics attack (PDA). In a PDA, the hacker connects to a node in the network of the CPS and injects false sensor data. Without proper readings from the sensors of the physical elements of the system, the control signals sent by the control algorithm to the physical actuators are incorrect, causing them to malfunction and behave in unexpected, potentially dangerous ways.

To address PDAs, the researchers adopted a technique known as software-defined networking (SDN), whereby the network of the CPS is made more dynamic by distributing the relaying of signals through controllable SDN switches. In addition, the proposed approach relies on a novel attack-detection algorithm embedded in the SDN switches, which can raise an alarm to the centralized network manager if false sensor data are being injected.

Once the network manager is notified, it not only cuts the cyberattacker off by pruning the compromised nodes but also establishes a new safe path for the sensor data. "Existing studies have only focused on attack detection, but they fail to consider the implications of detection and recovery in real time," explains Professor Kyung-Joon Park, who led the study, "In our study, we simultaneously considered these factors to understand their effects on real-time performance and guarantee stable CPS operation."

The new framework was validated experimentally in a dedicated testbed, showing promising results. Excited about the outcomes of the study, Park remarks, "Considering CPSs are a key technology of smart cities and unmanned transport systems, we expect our research will be crucial to provide reliability and resiliency to CPSs in various application domains." Having a system that is robust against cyberattacks means that economic losses and personal injuries can be minimized. Therefore, this study paves the way to a more secure future for both CPSs and ourselves.

Credit: 
DGIST (Daegu Gyeongbuk Institute of Science and Technology)

Large number of COVID-19 survivors will experience cognitive complications

A research review led by Oxford Brookes University has found a large proportion of COVID-19 survivors will be affected by neuropsychiatric and cognitive complications.

Psychologists at Oxford Brookes University and a psychiatrist from Oxford Health NHS Foundation Trust, evaluated published research papers in order to understand more about the possible effects of the SARS-COV-2 infection on the brain, and the extent people can expect to experience short and long-term mental health issues.

Patients experienced a range of psychiatric problems

The study found that in the short term, a wide range of neuropsychiatric problems were reported. In one examined study, 95% of clinically stable COVID-19 patients had post-traumatic stress disorder (PTSD) and other studies found between 17-42%* of patients experienced affective disorders, such as depression.

The main short-term cognitive problems were found to be impaired attention (reported by 45% patients) and impaired memory (between 13-28% of patients).

In the long term, neuropsychiatric problems were mostly affective disorders and fatigue, as well as impaired attention (reported by 44% of patients) and memory (reported between 28-50% of patients).

Mental health disorders could have significant impact on NHS

Dr Sanjay Kumar, Senior Lecturer in Psychology at Oxford Brookes University said: "Understanding the neuropsychiatric and cognitive consequences of COVID-19 is important as millions of people have been affected by the virus, and many cases go undetected. These conditions affect people's capacity to work effectively, drive, manage finances, make informed decisions and participate in daily family activities.

"If even just a fraction of patients experience neuropsychiatric complications, the impact on public health services could be significant."

Academics say that there is likely to be an increase in patients with psychiatric and cognitive problems who were otherwise healthy prior to COVID-19 infection.

"Detailed cognitive evaluation and robust monitoring of patients should be considered in order to detect new neurological cases," continues Dr Kumar.

"This will also enable health care providers to plan adequate health care and resources, and improve the quality of life for many COVID-19 survivors.

"These are emerging findings though, and we will learn much more as the research in the field progresses."

Co-author Dr Tina Malhotra, Consultant Psychiatrist working in Oxford Health NHS Foundation Trust said: "We are already seeing an impact of COVID -19 on mental health. Patients are presenting with Long COVID syndrome which includes fatigue, cognitive problems and a range of psychiatric problems.

"It is estimated that these problems are experienced by 1 in 5 people who have had COVID. Management of such patients in long-covid clinics should involve a multidisciplinary team including psychiatrists.

"NHS England has set out a recovery plan which includes setting up long covid clinics."

Credit: 
Oxford Brookes University

Magnetic whirls in confined spaces

image: Stable states with three, six, and ten skyrmions enclosed in a triangle. The plot shows time-averaged skyrmion positions from experiment (top row) and corresponding computer simulations (bottom row).

Image: 
ill./©: Jan Rothörl and Chengkun Song

In a close collaboration between experimental and theoretical physicists at Johannes Gutenberg University Mainz (JGU), the research groups of Professor Mathias Kläui and Dr. Peter Virnau investigated the behavior of magnetic whirls within nanoscale geometric structures. In their work published in Advanced Functional Materials, the researchers confined small magnetic whirls, so-called skyrmions, in geometric structures. Skyrmions can be created in thin metal films and have particle-like properties: They exhibit high stability and are repelled from each other and from specially prepared walls. Experiments and accompanying computer simulations showed that the mobility of skyrmions within these geometric structures depends massively on their arrangement. In triangles, for example, three, six, or ten skyrmions arranged like bowling pins are particularly stable.

"These studies lay the foundation for the development of novel non-conventional computing and storage media based on the movement of magnetic vortices through microscopic corridors and chambers," explained Professor Mathias Kläui. The research was funded by the Dynamics and Topology (TopDyn) Top-level Research Area, which was founded in 2019 as a collaboration between Johannes Gutenberg University Mainz, TU Kaiserslautern, and the Max Planck Institute for Polymer Research in Mainz. "This work is an excellent example for the interdisciplinary cooperation between simulation and experiment, which was only made possible by TopDyn's funding," emphasized Dr. Peter Virnau.

Credit: 
Johannes Gutenberg Universitaet Mainz

Determination of glycine transporter opens new avenues in development of psychiatric drugs

image: Unraveling the three-dimensional structure of the glycine transporter, researchers have now come a big step closer to understanding the regulation of glycine in the brain. These result open up opportunities to find effective drugs that inhibit GlyT1 function, with major implications for the treatment of schizophrenia and other mental disorders.

Image: 
Azadeh Shahsavar

Glycine can stimulate or inhibit neurons in the brain, thereby controlling complex functions. Unraveling the three-dimensional structure of the glycine transporter, researchers have now come a big step closer to understanding the regulation of glycine in the brain. These results, which have been published in Nature, open up opportunities to find effective drugs that inhibit GlyT1 function, with major implications for the treatment of schizophrenia and other mental disorders.

Glycine is the smallest amino acid and a building block of proteins, and also a critical neurotransmitter that can both stimulate or inhibit neurons in the brain and thereby control complex brain functions. Termination of a glycine signal is mediated by glycine transporters that reuptake and clear glycine from the synapses between neurons. Glycine transporter GlyT1 is the main regulator of neurotransmitter glycine levels in the brain, and also important for e.g. blood cells, where glycine is required for the synthesis of heme.

The N-methyl-D-aspartate (NMDA) receptor is activated by glycine, and its poor performance is implicated in schizophrenia. Over the past twenty years, many pharmaceutical companies and academic research laboratories therefore have focused on influencing glycinergic signaling and glycine reuptake delay as a way of activating the NMDA receptor in search of a cure for schizophrenia and other psychiatric disorders. Indeed, several potent and selective GlyT1 inhibitors achieve antipsychotic and pro-cognitive effects alleviating many symptoms of schizophrenia, and have advanced into clinical trials. However, a successful drug candidate has yet to emerge, and GlyT1 inhibition in blood cells is a concern for side effects. Structural insight into the binding of inhibitors to GlyT1 would provide insight in finding new strategies in drug design.

To gain better knowledge about the three-dimensional structure and inhibition mechanisms of the GlyT1 transporter, researchers from the companies Roche and Linkster, and from the European Molecular Biology Laboratory (EMBL) Hamburg, University of Zurich and Aarhus University, have therefore collaborated on investigating one of the most advanced GlyT1 inhibitors. Using a synthetic single-domain antibody (Linkster therapeutics'sybody®) for GlyT1, the research team managed to grow microcrystals of the inhibited GlyT1 complex. By employing a Serial Synchrotron Crystallography (SSX) approach, the team lead by Assistant Professor Azadeh Shahsavar and Professor Poul Nissen from the Department of Molecular Biology and Genetics/DANDRITE, Aarhus University, determined the structure of human GlyT1 using X-ray diffraction data from hundreds of microcrystals. The SSX method is particularly suitable as a method fornew, powerful X-ray sources and opens up for new approaches to, among other things, the development of drugs for various purposes.

The structure is reported in the leading scientific journal Nature and also unveils a new mechanism of inhibition in neurotransmitter transporters in general. Mechanisms have previously been uncovered for, for example, inhibition of the serotonin transporter (which has many similarities to GlyT1) with antidepressant drugs, but it is a quite different inhibition mechanism now found for GlyT1. It provides background knowledge for the further development of small molecules and antibodies as selective inhibitors targeted at GlyT1 and possibly also for new ideas for the development of inhibitors of other neurotrandmitter carriers that can be used to treat other mental disorders. Azadeh Shahsavar's team continues the studies of GlyT1 and will be investigating further aspects of its function and inhibition and the effect of GlyT1 inhibitors in the body.

Credit: 
Aarhus University